I vowed I would never post when family took precedence. I have to break that vow today. I wish I didn't but there is something so vitally important that I must share with you. Why is this important? Because it might save more lives than have been previously lost.
The scourge of Ovarian and Breast cancer has ravaged several populations. With very few cases of early detection in Ovarian cancer, many women present with spread of the cancer and very poor prognosis. Even more importantly, women who have ovarian cancer and BRCA mutations still are at risk for other cancers including breast cancer.
Despite this I have heard comments from Oncologists like "Why do we need testing?" This is why I have pulled myself away from my grief stricken family.
To fight this lack of knowledge I have dedicated and arm of Helix Health of Connecticut to educate and promote genomic medicine. This arm will host at minimum monthly podcasts on very important topics. The first of these is Hereditary Breast and Ovarian Cancers and the BRCA genes.
The panel will include a patient with BRCA1. She not only happens to be afflicted, she has written about her experiences. Jessica is gifted with the pen and is a very successful writer. Her book "Pretty is What Changes" raises significant issues and serves as a wake up call to clinicians and patients. It serves to empower us all.
Jessica will join David Ewing Duncan, bestselling author of Masterminds: Genius, DNA and the Quest to Rewrite Life, and a panel of distinguished medical and legal professionals to discuss how the doctor-patient relationship is changing and what the potential liability is for physicians in this new era of breast & ovarian cancer and genomic medicine.
The Sherpa Says:
The Helix Health of Connecticut webcast series is dedicated to my grandmother who died at 35 years of age from metastatic breast cancer. Too young for me to ever know. Please sign up for this conference. The information may just save a life......If Helix Health of Connecticut can save just one life then all the hard work is worth it. Please sign up now. Seats are limited, but you can also sign up for the podcast.
Friday, May 16, 2008
Heavy Heart
Posted by
Steve Murphy MD
at
10:43 AM
1 comments
Labels: 23 and me, barack obama, Breast cancer, family first, family history, Helix Health of Connecticut, navigenics, ovarian cancer
Tuesday, July 3, 2007
Which came first? The cancer or its chromosomes?
Posted by
Steve Murphy MD
at
6:20 PM
1 comments
Labels: aneuploidy, Breast cancer, chromosome, Colon cancer, gleevec, Lung cancer, mutation, ovarian cancer
Wednesday, May 16, 2007
Direct To Physician Testing... Myriad re-enters the fray.

According to my insider sources it appears that Myriad is going to launch a Direct To Consumer testing campaign for Hereditary Breast and Ovarian Cancers. Their quote is:
- "Because 1 out of 10 patients in your practice may be at risk for hereditary breast or ovarian cancer....Help Turn the Tide"
What happened the last time they campaigned? Demand for counseling went up 244% In addition there is a significant amount of literature that indicates the number one reason a "non-geneticist" orders a genetic test is patient request.
There are several ethical issues that need to be addressed with direct to consumer testing.
- A number of these tests lack data on their accuracy and reliability, making interpretation of results difficult.
- DTC genetic testing is undertaken outside the context of the physician-patient relationship and may lack appropriate individual and family genetic counseling,
- This often is leaving the consumer vulnerable to potential harms, such as misinterpretation of results, including false positive or false reassurance, with limited or no benefits
There are several solutions to these problems. None of which should exclude a trained health professional. Remember what I said before "beware the doctor peddling genetic tests"
The Gene Sherpa says: New York in October, the Avon Breast walk, Myriad and its DTC brokers will make some serious cash. Please make sure it is not at YOUR expense. Get the right follow up, get the continuity of care, and BEWARE NON-GENETICISTS SELLING GENETIC TESTS!
Posted by
Steve Murphy MD
at
8:15 AM
0
comments
Labels: BRCA, BRCA1, BRCA2, Breast cancer, direct to consumer, DNA, DNA direct, dna network, hboc, obstetrics, ovarian cancer
Wednesday, May 9, 2007
Mammography at 40
Recently the American College of Physicians (The Organization of Internal Medicine/ACP) released guidelines regarding mammography at 40 years of age. Until now the ACP guidelines were everyone 40 and over gets mammography. There is very little good literature that supports this previous recommendation, yet the American Cancer Society, ASCO, and ACOG still recommend that every woman 40 and above gets a mammo every 1-2 years. The ACP found that in their analysis the conclusion was "Although few women 50 years of age or older have risks from mammography that outweigh the benefits, the evidence suggests that more women 40 to 49 years of age have such risks." After reading the study and looking at the guidelines, they are not that drastic. Key Point Include
- Women 40-49 should have routine risk assessments for breast cancer risk. What is increased risk?
- 2 first degree relatives with breast cancer
- One with breast cancer and a previous breast biopsy(the patient)
- Previous breast cancer
- Previous noncancerous breast gland changes(DCIS, atypical hyperplasia)
- Prior chest irradiation (for cancers/not for a chest xray)
- BRCA1 or 2 mutations or family members with these mutations
- Physicians should inform these 40-49 year old women of the risks and benefits of mammography. What are the risks?
- False positive results (never shown to cause psychiatric problems:anxiety, depression etc.)
- Radiation exposure
- False reassurance from missed tumor
- Clinicians should base their screening mammography decisions on the woman's preference and risk profile.
The Gene Sherpa says: If you are younger than 50 mammography should be a collaborative choice between the physician and the patient. The problem?....When has a physician used a risk assessment tool to evaluate a patient for breast cancer? Sure cancer geneticists do this. But Internists? Sounds like we need some education for the internist, and for the patient. Would you get the mammogram?
Posted by
Steve Murphy MD
at
8:04 AM
0
comments
Labels: ACP, biopsy, BRCA, BRCA1, BRCA2, Breast cancer, gynecology, internal medicine, mammography, obstetrics, oncology, ovarian cancer, prostate cancer, radiation
